[Newsmp] Prostate cancer treatment Erleada Tab. passed the Drug Reimbursement Evaluation Committee (DREC) and received conditional insurance benefit, and Reba-eye and Reva-K Eye Drops have been accepted for benefit adequacy.
The Health Insurance Review & Assessment Service (HIRA, President: Kim Sun-min) released the results of deliberation at the 2022 12th DREC on Dec. 8.
The deliberation consists of two drugs (three items), Janssen Korea’s Erleada Tab. (ingredient: Apalutamide), Kukje Pharma’s Reba-eye Eye Drops 2% and Samil Pharmaceutical’s Reva-K Eye Drops, and all of them won insurance coverage.
Erleada Tab. applied for a determination on metastatic hormone-sensitive prostate cancer (mHSPC) with efficacy and effectiveness and gained benefit adequacy when accepting the conditions presented by the DREC.
Reba-eye Eye Drops and Reva-K Eye Drops received benefits for efficacy and effectiveness in corneal epithelial disorders in adult patients with dry eye syndrome.
Each pharmaceutical company plans to negotiate drug prices with the National Health Insurance Service in the future.
